Recent News

• 10.27.2026 - Facilities and Maintenance Coordinator
• 10.07.2026 - Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
• 09.23.2026 - Clinical Supply Manager
• 09.23.2026 - Clinical Research Associate (CRA)
• 09.23.2026 - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
• 09.21.2026 - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
• 09.14.2026 - Lead Clinical Research Associate (Lead CRA)
• 09.14.2026 - Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
• 09.10.2026 - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
• 09.03.2026 - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Recent Filings

• 09.23.2026 - 8-K Current report
• 09.23.2026 - EX-99.1 EX-99.1
• 09.14.2026 - 8-K Current report
• 09.14.2026 - EX-99.1 EX-99.1
• 08.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2026 - 8-K Current report
• 08.12.2026 - EX-99.1 EX-99.1
• 07.20.2026 - 8-K Current report
• 07.20.2026 - 8-K Current report
• 07.20.2026 - EX-99.1 EX-99.1